日本的研究发现,CathWorks FFFRANGio在节省成本和资源较少的情况下,为传统方法提供了类似的临床结果。 Japanese study finds CathWorks FFRangio offers similar clinical outcomes to traditional methods with cost savings and fewer resources.
在日本进行的一项随机对照试验,即 PROVISION 研究,评估了 CathWorks FFRangio® 系统,这是一种用于诊断冠状动脉疾病的非侵入性技术. The PROVISION Study, a randomized controlled trial in Japan, evaluated the CathWorks FFRangio® System, a non-invasive technology for diagnosing coronary artery disease. 调查发现,FFRANGio为传统的有线方法提供了类似的临床结果,同时将每个病人的费用减少约374美元至400美元,并需要较少的资源。 It found that FFRangio offers similar clinical outcomes to traditional wire-based methods while reducing costs by about $374 to $400 per patient and requiring fewer resources. 这项研究强调了FFRANGio的效率、降低辐射照射和增强病人的舒适度,标志着心血管诊断方面的显著进步。 The study highlights FFRangio's efficiency, lower radiation exposure, and enhanced patient comfort, marking a significant advancement in cardiovascular diagnostics.